Efficacy and Safety Evaluation of ALT-836 in Patients With Sepsis and Acute Lung Injury/Acute Respiratory Distress Syndrome

Trial Profile

Efficacy and Safety Evaluation of ALT-836 in Patients With Sepsis and Acute Lung Injury/Acute Respiratory Distress Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs ALT 836 (Primary)
  • Indications Acute lung injury; Respiratory distress syndrome; Sepsis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Altor BioScience Corporation
  • Most Recent Events

    • 09 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 24 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top